Clinical Trials

220 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT05848011 2026-05-22

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

154 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT06717347 2026-05-22

MK-2140-010

1,046 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06890884 2026-05-22

MK-2140-011

594 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06925737 2026-05-22

MK-2400-001

1,440 enrolled

Prostatic Neoplasms

NCT06911502 2026-05-20

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

400 enrolled

Lymphoma, Follicular

NCT06091254 2026-05-19

OLYMPIA-1

822 enrolled

Lymphoma, Follicular

NCT06952803 2026-05-19

EvoPAR-PR02

700 enrolled

Prostatic Neoplasms

NCT06091865 2026-05-15

OLYMPIA-3

904 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06564038 2026-05-14

Soundtrack-E

408 enrolled

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT02257736 2026-05-11

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

982 enrolled 15 charts

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03431350 2026-05-11

QUEST

136 enrolled 29 charts

Prostatic Neoplasms, Castration-Resistant

NCT04497844 2026-05-11

AMPLITUDE

696 enrolled 15 charts 1 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT07225946 2026-05-11

KLK2-PASenger

800 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT02123758 2026-05-08

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

57 enrolled

Prostatic Neoplasms

NCT03274492 2026-05-08

POLARIX

Phase 3 Completed

1,000 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT03748641 2026-05-08

MAGNITUDE

765 enrolled 16 charts 1 FDA

Prostatic Neoplasms, Castration-Resistant

NCT04577833 2026-05-08

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

136 enrolled

Prostatic Neoplasms

NCT04662580 2026-05-08

ARX517

183 enrolled

Prostatic Neoplasms

NCT05818683 2026-05-08

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Phase 1 Recruiting

300 enrolled

Metastatic Castration-resistant Prostate Neoplasms

NCT05283720 2026-05-06

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06191744 2026-05-06

EPCORE™FL-2

1,095 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT04542824 2026-05-05

EPCORE™ NHL-3

78 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04623541 2026-05-05

EPCORE™ CLL-1

195 enrolled

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04663347 2026-05-05

EPCORE™ NHL-2

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT06136624 2026-05-05

OMAHA-003

1,310 enrolled

Prostate Cancer Metastatic

NCT07365995 2026-05-05

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

736 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT07005154 2026-05-01

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

218 enrolled

Phase 2/3 Active not recruiting

Prostatic Neoplasms

NCT03706365 2026-04-24

CYCLONE 2

393 enrolled 23 charts

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT05457257 2026-04-21

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

43 enrolled 16 charts

Metastatic Castration-resistant Prostate Cancer

NCT04884035 2026-04-17

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Phase 1 Recruiting

224 enrolled

Lymphoma, B-Cell

NCT05888493 2026-04-17

LEDA

109 enrolled

Lymphoma, Follicular, Recurrence

NCT02960022 2026-04-13

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

900 enrolled

Prostatic Neoplasms

NCT07221838 2026-04-09

OCTAGON

Phase 4 Recruiting

75 enrolled

Adrenal Insufficiency, Myasthenia Gravis

NCT04231448 2026-04-08

DEB

Phase 3 Completed

423 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04824092 2026-04-01

frontMIND

899 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04529772 2026-03-31

ESCALADE

611 enrolled

Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06421935 2026-03-24

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

141 enrolled

Gynecologic

Ovarian Neoplasms

NCT05489211 2026-03-19

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

GastrointestinalGynecologic

454 enrolled

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06313996 2026-03-18

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Phase 3 Withdrawn

Lymphoma, Follicular, Recurrence

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

BreastGynecologicThoracic

182 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02723994 2026-03-11

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

171 enrolled

Burkitt Lymphoma, Leukemia

NCT04179864 2026-03-10

CELLO-1

Phase 1/2 Terminated

102 enrolled 39 charts

Prostatic Neoplasms

NCT01314118 2026-02-24

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

131 enrolled 12 charts

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03407144 2026-02-19

MK-3475-667

340 enrolled

Hodgkin Disease

NCT04569032 2026-02-18

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

82 enrolled 13 charts

Lymphoma, T-Cell, Peripheral

NCT07339267 2026-02-18

A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer

Phase 1 Recruiting

12 enrolled

Prostatic Neoplasms

NCT02861573 2026-02-17

KEYNOTE-365

1,200 enrolled

Phase 2 Active not recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT04980222 2026-02-17

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

46 enrolled